Key result
Surgical myectomy outperforms ablation for HOCM, offering fewer complications and more complete obstruction relief.
Why the study?
Does surgical myectomy provide better outcomes than percutaneous ablation in patients with hypertrophic obstructive cardiomyopathy?
Does surgical myectomy provide better outcomes than percutaneous ablation in patients with hypertrophic obstructive cardiomyopathy?
Surgical myectomy remains the gold standard for hypertrophic obstructive cardiomyopathy, providing superior and more lasting relief of obstruction with fewer complications than percutaneous ablation.
Supports myectomy preference in obstructive HCM; leaves open need for randomized trials to confirm ablation alternatives.
Hypertrophic cardiomyopathy ranks among the most common congenital cardiac diseases, affecting up to 1 in 200 of the general population. When it causes left ventricular outflow tract obstruction, treatment is guided to reduce symptoms and the risk of sudden cardiac death. Pharmacologic therapy is the first-line treatment, but when it fails, surgical myectomy or percutaneous ablation of the hypertrophic myocardium are the standard therapies to eliminate subaortic obstruction. Both surgical myectomy and percutaneous ablation are proven safe and effective treatments; however, myectomy is the gold standard with a significantly lower complication rate and more complete and lasting reduction of left ventricular outflow tract obstruction.
No takes yet. Share an insight, caveat, or question.
Price et al. (2017) conducted a review in Hypertrophic obstructive cardiomyopathy. Surgical myectomy vs. Percutaneous ablation was evaluated. Surgical myectomy is the gold standard treatment for hypertrophic obstructive cardiomyopathy, offering a significantly lower complication rate and more complete reduction of obstruction than ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: